SkQ1

Targeted Mitochondrial Delivery via Membrane Potential#

SkQ1 is a "Skulachev ion" — a plastoquinone redox head group tethered by a 10-carbon linker to a decyltriphenylphosphonium (TPP⁺) cation. The TPP⁺ moiety is lipophilic enough to cross membranes but carries a permanent positive charge, so it is pulled down the steep electrical gradient of the inner mitochondrial membrane (~−150 mV) and trapped in the matrix. The result: SkQ1 concentrates several hundred- to ~1000-fold inside mitochondria relative to extracellular fluid, which is why nanomolar tissue concentrations are biologically active and why oral microgram dosing is sufficient.

"The unique feature of SkQ1 is its ability to accumulate within mitochondria at concentrations several orders of magnitude higher than outside the cell, specifically neutralizing mitochondrial ROS and preventing cardiolipin peroxidation." — Skulachev VP, Anisimov VN, Antonenko YN, et al., BBA Bioenergetics (2009)

Practical consequence: SkQ1 is dose-flat across bodyweight in a way most compounds are not. The target is a subcellular compartment, not a systemic receptor pool, so 250 µg is 250 µg whether the subject is 70 kg or 110 kg.

Cardiolipin Protection and Lipid Peroxyl Scavenging#

Once parked at the inner membrane, the plastoquinone head is reduced to plastoquinol by the respiratory chain and then directly scavenges lipid peroxyl radicals and cardiolipin peroxides. Cardiolipin is the signature phospholipid of the inner mitochondrial membrane, and its peroxidation is an early, irreversible step in mitochondrial dysfunction — it disrupts cristae architecture, destabilizes respiratory supercomplexes, and releases cytochrome c to trigger apoptosis.

Plastoquinone (borrowed from chloroplast electron transport) has a substantially wider antioxidant "window" than ubiquinone before it flips pro-oxidant, which is the chemistry reason SkQ1 outperforms ubiquinone-based analogs like MitoQ at low concentrations. For the bodybuilding and looksmaxxing reader, the relevant downstream is cardiomyocyte and hepatocyte protection during heavy oral AAS or long blast-and-cruise protocols, where mitochondrial ROS load is chronically elevated.

Suppression of mtROS-Driven Inflammatory Signalling#

Mitochondrial ROS act as a second messenger for NF-κB, p38 MAPK, ERK1/2, and the NLRP3 inflammasome. By interrupting ROS production at the source, SkQ1 dampens this entire inflammatory cascade rather than blocking a single downstream cytokine. In activated human neutrophils, this translates to measurable suppression of 5-lipoxygenase activity and the leukotriene B4 axis.

"SkQ1 suppressed mitochondrial ROS production and the activation of 5-lipoxygenase, resulting in reduced leukotriene B4 synthesis in activated human neutrophils." — Sud'ina GF, Golenkina EA, Prikhodko AS, et al., Front Pharmacol (2022)

Importantly, the bare TPP⁺ tail (C12TPP) without the plastoquinone head does not reproduce these effects, which rules out mild uncoupling as the mechanism. The benefit is genuinely from antioxidant chemistry inside the mitochondrion.

Reversal of Senescence-Associated Endocrine Drift#

The most striking systemic finding in the Skulachev rodent work is partial restoration of an aged endocrine profile toward a younger one — without any direct hormonal activity from the molecule itself.

"Chronic administration of SkQ1 (250 nmol/kg/day) reversed age-dependent changes in IGF-1, testosterone, DHEA, and GH observed in old rats toward levels typical for young animals." — Kolosova NG, Stefanova NA, Muraleva NA, Skulachev VP, Aging (2012)

The mechanistic interpretation: chronic mitochondrial oxidative stress drives cellular senescence in Leydig cells, somatotrophs, and adrenal cortex tissue. Relieving that stress allows partial recovery of endocrine output. This is not a TRT substitute — the effect is reversal of decline in already-senescent tissue, not stimulation of healthy tissue — but it does explain why SkQ1 sits in the longevity-stack rotation alongside rapamycin and NAD+ precursors rather than as a standalone hormonal lever.

Geroprotection and Lifespan Extension#

Across fungi, crustaceans, drosophila, fish, and multiple mouse strains, chronic low-dose SkQ1 has reproducibly extended median lifespan and delayed age-related pathology — cataracts, cardiac hypertrophy, retinopathy, osteoporosis, and immune senescence.

"SkQ1 added to drinking water in very low doses (0.5–250 nmol/kg/day) delayed appearance of numerous age-related traits and increased lifespan in rodents." — Anisimov VN, Egorov MV, Krasilshchikova MS, et al., Aging (2011)

The dose-response is bell-shaped: too little does nothing, too much flips plastoquinol from antioxidant to pro-oxidant once mitochondrial concentrations exceed the buffering capacity of the local lipid environment. This is why the protocol caps near 250 µg/day and why stacking SkQ1 with high-dose MitoQ is discouraged — they share the same mitochondrial pool and the same flip threshold.

Ocular Surface Mechanism (Visomitin)#

Topically, the same mitochondrial-ROS suppression mechanism protects corneal and conjunctival epithelium against oxidative injury from screen exposure, contact lenses, isotretinoin-induced lacrimal dysfunction, and post-LASIK dry eye. This is the only SkQ1 indication with phase 3 human RCT data and the only application where systemic PK is irrelevant — the drug acts at the tissue surface and never needs to reach plasma.

"A statistically significant therapeutic effect of Visomitin (SkQ1) eye drops was observed in the improvement of objective signs of dry eye syndrome after six weeks of therapy." — Brzheskiy VV, Efimova EL, Vorontsova TN, et al., Adv Ther (2015)

For the looksmaxxing reader running isotretinoin or stacking heavy screen time onto an aesthetics protocol, Visomitin is the cleanest, best-evidenced piece of the SkQ1 toolkit.

Common (most users)#

The community read on SkQ1 at the standard 250 µg/day oral dose is that most users feel nothing — which is the expected profile for a slow-acting geroprotector. The published Visomitin trials saw only mild, transient ocular effects, and systemic forum reports are consistent with that.

• Mild GI upset / nausea — uncommon at 250 µg/day. Mitigated by administering with a fatty meal (TPP⁺ amphiphiles partition with dietary lipid, which also smooths absorption).
• Transient ocular stinging or redness (Visomitin) — most common topical complaint, comparable to artificial-tear vehicle in the Brzheskiy RCT. Resolves within minutes; no dose adjustment needed.
• Mild conjunctival irritation (Visomitin) — pause for 24–48 hours if persistent, then resume at 2× daily instead of 3×.
• Subjective "nothing happening" — not a side effect, but the most common forum complaint. SkQ1 is not a stim or a peptide with an acute training feel; the endpoint is biomarker drift over months. Dose creep in pursuit of a feel is the single most common mistake.

"A statistically significant therapeutic effect of Visomitin (SkQ1) eye drops ... was observed in the improvement of objective signs of dry eye syndrome after six weeks of therapy." — Brzheskiy et al., Adv Ther (2015)

Uncommon (dose-dependent or individual)#

These are the effects that show up when the protocol drifts above ~500 µg/day or when SkQ1 is doubled-up with another mitochondria-targeted antioxidant.

• Pro-oxidant flip at supraphysiologic intake — every mito-TPP antioxidant reverses polarity above a tissue-specific concentration. The rodent dose-response is bell-shaped; running 1–2 mg/day "to feel something" is the protocol most likely to produce this. Back off to 250 µg/day and reassess.
• Headache / mild fatigue during the first 1–2 weeks — reported anecdotally on LongeCity and r/Nootropics, typically self-resolving. If persistent, drop to 125 µg/day for two weeks and titrate back.
• Reduced effect over very long continuous runs — community-reported, not formally characterized. The 5-on / 2-off pulsing pattern exists for this reason and is worth considering on 6-month-plus protocols.
• Subclinical inflammatory marker shifts — in either direction. hsCRP is the cheapest readout; the community standard is baseline + 6-month CBC, CMP, lipids, hsCRP.

Rare but serious#

No serious adverse events have been published in the Visomitin clinical program or in any systemic preclinical work at sane doses. The following are mechanism-derived concerns that warrant stopping the protocol and reassessing:

• Cardiac symptoms (palpitations, chest discomfort) — lipophilic TPP⁺ cations have shown mild cardiac signal in some high-dose rodent work. Clinically unobserved with SkQ1, but a reason to keep doses modest and to investigate any new symptom rather than push through.
• Worsening of an underlying mitochondrial disorder — cells with collapsed Δψ do not concentrate the drug normally and the safety profile in this population is unknown. Discontinue.
• Signs consistent with oxidative overshoot at supraphysiologic doses — rising hsCRP, ferritin, or LDL oxidation markers alongside subjective decline. Discontinue and re-baseline.

Hard contraindications#

• Pregnancy and lactation — no safety data. Do not use.
• Known mitochondrial disease (MELAS, Leigh syndrome, primary mtDNA disorders) — Δψ dynamics are abnormal; the compound's accumulation behavior is unpredictable. Defer to specialist input.
• Concurrent high-dose MitoQ or other full-dose mitochondria-targeted antioxidants — shared mitochondrial pool, redundant target, additive pro-oxidant risk. Pick one.
• Active melanoma or other malignancy under treatment — antioxidant interactions with cytotoxic chemotherapy are context-specific and outside the documented use case.

Gender, PCT, and stack considerations#

SkQ1 is non-hormonal — no androgenic, estrogenic, or HPTA activity. It does not require PCT, does not interfere with SERMs or AIs, and the dose is bodyweight-independent (same 250 µg/day across the audience). The Kolosova rodent data showing restoration of GH, IGF-1, testosterone, and DHEA toward younger values reflect reversal of senescence-driven decline in old animals — they do not make SkQ1 a TRT-adjacent compound and it should not be framed that way.

"Chronic administration of SkQ1 (250 nmol/kg/day) reversed age-dependent changes in IGF-1, testosterone, DHEA, and GH observed in old rats toward levels typical for young animals." — Kolosova et al., Aging (2012)

For on-cycle users: SkQ1 targets the mitochondrial-lipid-peroxidation arm of cycle stress and nothing else. It complements TUDCA, NAC, telmisartan, and BP/lipid management — it does not replace any of them. Treating it as primary cycle support is the second most common mistake after dose creep.